Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you. I will! Sounds like a great company!!!
I thought all Analysts got paid for providing coverage.
Any idea why the stock acted so strangely today? It looked at one point like trading had been halted!?
That is a very realistic and EXCELLENT justification of your theory. I like it and thank you for taking the time to post it.
Biomedreports' latest
Once their news story on BMTL hits the news wires this morning it's gonna fly! They always do.
Check out the "better mousetrap" story on the front page.
http://biomedreports.com/
BMTL ready to breakout after today's news
Did you guys see the BioMedReports story? Once this hits the wires it's gonna go nutz!
http://biomedreports.com/component/content/article/56-top-leading-news/21762-medical-waste-a-better-mouse-trap-is-ready-to-generate-green-profits-otcbmtl.html
See the BioMedReports story? Once this hits the wires it's gonna go nutz!
http://biomedreports.com/component/content/article/56-top-leading-news/21762-medical-waste-a-better-mouse-trap-is-ready-to-generate-green-profits-otcbmtl.html
As soon as that biomedreport hits the news wires it's gonna make the stock go nuts.
amigo.. What do you think this thing goes to by Jan 07?
Thanks for doing that! Looking forward to the video.
I'd love for Clay trader to chime in too!
Report now available free to everyone!
http://biomedreports.com/articles/most-popular/21414-goldman-small-cap-research-covers-medclean-otcmcln.html
Goldman Small Cap Research Covers MedClean (OTC:MCLN)
Former Piper Jaffray's Technology analyst Rob Goldman, who brings over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager has initiated coverage on MedClean (OTC:MCLN).
In his report (available for free download to members of BioMedReports) he gives the stock a near-term target of $0.14 and an early 2010 price target of $0.40.
Complete story is in the members only section of BiomedReports.Com
Goldman Small Cap Research Covers MedClean (OTC:MCLN)
Senior research analyst rates MedClean a "Speculative Buy" and believes share price could reach $0.40 early next year as the company executes its plan.
Former Piper Jaffray's Technology analyst Rob Goldman, who brings over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager has initiated coverage on MedClean (OTC:MCLN).
In his report (available for free download to members of BioMedReports) he gives the stock a near-term target of $0.14 and an early 2010 price target of $0.40.
During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology research team covering Israeli Technology and Communications Software. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group as well as the Firm's Israeli research team. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.
What do you men when you say "8 days to cover?" Please explain.
Goldman Small Cap Research Covers MedClean (OTC:MCLN)
Staff and Wire Reports
Wednesday, 09 December 2009 04:52
Senior research analyst rates MedClean a "Speculative Buy" and believes share price could reach $0.40 early next year as the company executes its plan.
Rob Goldman, a former Piper Jaffray's analyst with over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager has initiated coverage on MedClean (OTC:MCLN). In his report (available for free download to members of BioMedReports) he gives the firm a near-term target of $0.14 and an early 2010 price target of $0.40.
During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology research team covering Israeli Technology and Communications Software. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group as well as the Firm's Israeli research team. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.
link:
http://biomedreports.com/articles/subscriber-only-content/21414-goldman-small-cap-research-covers-medclean-otcmcln.html
I thought biomedreports said that sometime this week a Wall Street Analyst was going to cover MCLN?
Another one from Stockhouse---
http://www.stockhouse.com/News/USReleasesDetail.aspx?n=7559577
It looks like this same GCKO article is going viral. Now it's on Trading Markets---
http://www.tradingmarkets.com/.site/news/Stock%20News/2708941/
Silicon Valley Newspaper on GCKO too!
http://studio-5.financialcontent.com/mng-ba.mercurynews/?GUID=11048709&Page=MediaViewer&Ticker=IRBT
San Jose Mercury News (Silicon Valley) paper on GCKO!!!
http://studio-5.financialcontent.com/mng-ba.mercurynews/?GUID=11048709&Page=MediaViewer&Ticker=IRBT
***CBS Moneywatch on GCKO!***
This will help it move now.
http://finance.bnet.com/bnet/?GUID=11048709&Page=MediaViewer
CBS MoneyWatch on GCKO!!!
http://finance.bnet.com/bnet/?GUID=11048709&Page=MediaViewer
With big news and coverage coming it will only go up from here.
Geckosystems International (GCKO.PK) and iRobot Corp. (NASDAQ:IRBT) listed as hottest robotics stocks to own
Robotic stocks to watch in the days ahead include iRobot Corp. (NASDAQ:IRBT), whose share price have already more than doubled in the past year.
On Monday, the company announced that Colin Angle, iRobot’s Chairman and CEO, will present at the FBR Capital Markets 2009 Fall Investor Conference being held at the Grand Hyatt Hotel in New York on December 2, 2009. The CEO is expected to discuss some news regarding the strategic direction of the company and Wall Street will be monitoring his presentation closely given the recent news and attention that the robotic sector has been getting.
iRobot aims to "build robots that make a difference" and the company's consumer and military robots feature their AWARER robot intelligence systems, a proprietary technology which incorporates advanced concepts in navigation, mobility, manipulation and artificial intelligence.
If you feel you may have missed the bus with share prices for IRBT now at over $16 per share, then you may want to pick up shares of their $1.6 million penny stock competitor, Geckosystems International (GCKO.PK).
The Georgia based company is expected to announce that it will be moving its CareBot eldercare/health care robot prototype from current in-home trails to production. The company aims to compete with iRobot's new health care robot division with similar patented technologies designed to help the elderly.
At the IFA gadgets show in Berlin earlier this year, iRobot CEO Colin Angle told reporters that robotic telepresence devices, like GCKO's which would act like nurses in people's homes, could reduce the $2.2 trillion, or 17 percent of the U.S. GDP, currently spent on health care every year.
If news is announced by Geckosystems, shares may continue to rise well beyond their 52-week highs to at least the mid-dollar level.
New reports that the company may partner with a yet to be named, NASDAQ listed company on mass production of their robots in the coming days. Several outside contract manufacturers have been identified and the company aims to produce up to 1,000 CareBots per month within four to six months.
On Friday, institutional type buyers moved in on millions of blocks of the company's shares sending GCKO's stock up 600% from $.006 to $.04.
Shares re-traced when trading commenced on Monday, but gave back only 39% of those big gains, mostly to profit taking in the early part of the day.
In Japan, home to one of the world's most rapidly aging populations, the Japanese government has granted over $100M in R&D funding to the cause and there are currently two robots prototypes which aim to help the elderly. Unfortunately, investors do not have an opportunity to cash in on the trend there.
One project called Riba, short for Robot for Interactive Body Assistance, was developed by the state-run Riken research center. The "nurse bot" lifts elderly patients from wheelchairs and beds.
Another robot, Taizo, is a humanoid bot that leads Japanese seniors in calisthenics. That robot was developed by Japan's National Institute of Advanced Industrial Science and Technology (AIST), a state-run research center, and a privately held spinoff company called General Robotix.
Unfortunately, while many perceive the Japanese are world leaders in personal robot development, no viable commercial products have been developed in the field of eldercare personal companion robots.
I feel it too. Good luck!!!
I agree. Looks very solid!
I agree. They can't argue that this stock is going to move now!
Biomed says gcko has big news coming:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=44285118
Okay. Here it is, from the subscribers section of biomedreports:
The following is an update on two stocks which we previously issued a watchlist alert on.
One of the companies traded down on Monday even after enthusiastic buyers showed up eager to buy shares this morning. This is one of the big reasons why we didn't issue a TRADE alert- only a WATCH alert (read the difference here).
Although shares of GeckoSystems Intl. Corp. (OTC:GCKO) were down 39% from their Friday close, on the stock had run up over 600% in the closing minutes of the market prior to us reaching out to our investors via e-mail.
While some expected a pull back after such a dramatic rise, the type of selling we observed at the begining of the market day was one of the reasons we were suspicious that the stock might be the target of pump and dumpers. Still, it speaks volumes about the bullish strength of the stock that it only gave up 39% by the end of the day on Monday. This appears to indicate that most of the new buyers held on to their shares.
Only now would we encourage subscribers/readers to acquire shares of this stock on the dips. we do this as we advise you- as always- to do your own due diligence. It is important to note that BioMedReports spoke to representatives of GCKO and that in our own opinion institutional-type buying occured on Friday afternoon due to an upcoming key development for the company. As far as we can tell, that development is something which the markets are expecting and that may position GeckoSystems' price per share in a higher trading range going forward as well.
Since the news may include up to two publicly traded companies, we will try to speak to representatives from those companies for that report, although one of the companies has not returned calls as of the time of this alert. After completing our investigation, BioMedReports will issue a full report along with our opinion this week.
It is our sincere hope that the report will be issued ahead of the key development(s), but since we can not control the news flow or events, there are no guarantees that we will succeed in this endeavor.
Please see the GCKO's chart below for more information.
In other news, shares of BioMedical Technology Solutions (OTC:BMTL) closed up 13% on very little volume.
A profile report on that company will also appear in the coming days. As reported to our subscribers earlier, that company appears ready to announce some positive developments which may also impact share prices going forward.
Disclosure: No Positions
Oh sh*t! huge news leak from biomedreports to their subscribers about GCKO.
MCLN looks solid through and through. Thanks for posting that!
My favorite quote from Biomed's interview:
"Several billion dollars a year are spent in the offsite hauling of regulated medical waste, so there is tremendous market opportunity. The companies in the market for onsite treatment of waste are small and fragmented. The good news in this is that it is a largely untapped market. So this is a multibillion dollar market opportunity that renews every year. The hospitals never stop making infectious waste. So, it is a very underpenetrated market and no company has emerged with the capability and scalability to be a significant player and we need to be that significant player."
--Scott Grisanti, Chairman of the board, MCLN
It's interesting and very smart tht you bring up VRMLQ. The reason their share price went nuts is because they also had very few shares in the float. VERY few shares. Just like this one.
Deewar,
Is your name really Adam Fuc*stein? He has a hard-on against biomedreports because they always make him look like the bald little circumcized fool that he is.
When was the last time anyone made money listening to his picks or those of his tool of a boss boss Jim Cramer?
You go try to figure that one out.
In the meantime, I'll keep making money.
SIGA- is that another one of their P&D's? It went nuts after they
wrote about it. Hasn't looked back since.
Not to mention Acorda Therapeutics. When the Street and others were bashing it at $14.89 they wrote about and it bounced back to $26.
DNDN- same thing.
Big bounces on both. Just like that.
These guys know their shit and are rockin' the street.
The old guard can't stand them. Sounds like you're one of them.
Its simple. If they say buy, people do. I'm in line all the way to the bank.
GCKO is gonna gap and run from here. Looks like another VKNG run, except better because this one has less shares. If you sneeze while buying shares the price moves up. It's cray-z!
There are so few shares available, that it will probably gap up and continue running.
Piano,
The fundamentals on this company are so good that it's gonna run regrdless of who is being biased or has positions. Plus a wall street analyst is supposed to do coverage on this thing this week. Who cares what you and i think. We're just little guys. Kapeeesh?
Did I miss the train on GCKO or will this run up more?
Insiders own 72% of all shares and there is no visible overhang on this thing.
The buys on Friday were HUGE blocks. Millions of shares each.
Someone knew something. Then all of a sudden 24 hours later, the U.S. News and World Report article appears.
Two thoughts:
1- You don't do a pump and dumb minutes before the market closes on a friday
2- The float is so small this thing is gonna move up almost by itself very quickly
3- Lots of eyeballs on this stock all of a sudden. Someone knew something.